Skip to main content
Caplight Logo









Origami Therapeutics

Origami Therapeutics

Private
San Diego, CaliforniaHealthcare & Life Scienceshttps://origamitherapeutics.com/

Last Round

Crowdfunding

Nov 14, 2023

Total Funding Raised

$6.62M

Company Overview

Origami Therapeutics is a biopharmaceutical company that develops disease-modifying treatments for neurodegenerative disorders using protein degraders and small molecule correctors.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Application

Keywords

protein degradationsmall-molecule drugsdrug discoveryneurodegenerative diseasetargeted protein degradationTPDbiotech R&Dundruggable targetscomputational chemistrydrug discovery platformbiotech licensingPROTACsAI-augmented drug discoverypreclinical biotech

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Origami Therapeutics Comparables

Compare Origami Therapeutics with similar companies based on industry and business-model similarity.

Origami Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Plexium
89%
TRIMTECH Therapeutics
85%
Prazer Therapeutics
83%

Origami Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
CrowdfundingNov 14, 2023
GrantSep 1, 2022
SeedApr 1, 2022

Origami Therapeutics Investors

Notable investors and investment history

Origami Therapeutics investors
InvestorRounds
Catalytic Impact FoundationSeed
Y CombinatorSeed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jan 30, 2026

    Partnered with Ipsen to develop a protein degrader program for a rare neurodegenerative disorder.

  • Jan 30, 2026

    Partnered with Ipsen to develop a small-molecule protein degrader program.

Origami Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Origami Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Origami Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersSan Diego, California
Employee Range7
Year Founded2015
Last FundingNov 14, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?